Literature DB >> 354733

Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients.

I F Brockington, R E Kendell, J M Kellett, S H Curry, S Wainwright.   

Abstract

Two drug trials in schizoaffective patients are reported. Nineteen "schizomanic" patients were treated for one month, on a double blind basis, with chlorpromazine or lithium and 41 "schizodepressive" patients with amitriptyline, chlorpromazine or both. In the schizodepressive patients there was a trend to a better response to chlorpromazine, but drug response generally was poor, only 20 per cent of patients recovering within the month. In the schizomanic patients lithium seemed as effective as chlorpromazine, which supports the view that these patients were suffering from a variant of mania.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 354733     DOI: 10.1192/bjp.133.2.162

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  10 in total

1.  Lithium for acute mania.

Authors:  Rebecca F McKnight; Saïk J G N de La Motte de Broöns de Vauvert; Edward Chesney; Ben H Amit; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-06-01

2.  Use of antidepressants in schizophrenia.

Authors: 
Journal:  Br Med J       Date:  1980-04-12

Review 3.  Evaluation of newer treatment interventions for psychotic depression.

Authors:  B L O'Neal; C L Smith; M Trivedi
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

4.  Role of paliperidone extended-release in treatment of schizoaffective disorder.

Authors:  Carla M Canuso; Ibrahim Turkoz; Dong Jing Fu; Cynthia A Bossie
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

5.  Schizophrenia and bipolar disorder are distinguished mainly by differences in neurodevelopment.

Authors:  Jenny Walker; Vivienne Curtis; Philip Shaw; Robin M. Murray
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 6.  Pharmacologic treatment of schizoaffective disorder.

Authors:  P E Keck; S L McElroy; S M Strakowski; S A West
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

Review 7.  Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis.

Authors:  Rina Dutta; Talya Greene; Jean Addington; Kwame McKenzie; Michael Phillips; Robin M Murray
Journal:  Schizophr Bull       Date:  2007-06-11       Impact factor: 9.306

Review 8.  Depression in schizophrenia: current guidelines to treatment.

Authors:  S J Bartels; R E Drake
Journal:  Psychiatr Q       Date:  1989

9.  The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.

Authors:  Diego Quattrone; Ulrich Reininghaus; Alex L Richards; Giada Tripoli; Laura Ferraro; Andrea Quattrone; Paolo Marino; Victoria Rodriguez; Edoardo Spinazzola; Charlotte Gayer-Anderson; Hannah E Jongsma; Peter B Jones; Caterina La Cascia; Daniele La Barbera; Ilaria Tarricone; Elena Bonora; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Manuel Arrojo; Andrea Tortelli; Eva Velthorst; Steven Berendsen; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; James B Kirkbride; Pak C Sham; Michael C O'Donovan; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Robin M Murray; Cathryn M Lewis; Marta Di Forti
Journal:  Transl Psychiatry       Date:  2021-08-10       Impact factor: 6.222

Review 10.  Lithium for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.